logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Regulatory And Economic Aspects In Oncology 1st Ed Evelyn Walter

  • SKU: BELL-7320396
Regulatory And Economic Aspects In Oncology 1st Ed Evelyn Walter
$ 31.00 $ 45.00 (-31%)

5.0

108 reviews

Regulatory And Economic Aspects In Oncology 1st Ed Evelyn Walter instant download after payment.

Publisher: Springer International Publishing
File Extension: PDF
File size: 2.93 MB
Author: Evelyn Walter
ISBN: 9783030012069, 9783030012076, 3030012069, 3030012077
Language: English
Year: 2019
Edition: 1st ed.

Product desciption

Regulatory And Economic Aspects In Oncology 1st Ed Evelyn Walter by Evelyn Walter 9783030012069, 9783030012076, 3030012069, 3030012077 instant download after payment.

This book explores topics of importance to all who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to their marketing authorization and pricing. Targeted therapies and modern immunotherapy are placing a substantial strain on health care budgets. Regulation and economic methods to assess the parameters for establishing efficacy and effectiveness are therefore of prime importance. Payer authorities have to determine whether the use of these novel therapies yields clinical benefits that justify their increasing cost. In the simplest terms, cost-effectiveness analyses quantify the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulations must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-costs research programs. Ultimately, decisions regarding health care expenditures are also a question of society’s willingness to pay.


Related Products